Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials.
about
Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant dataPostinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancerThe long-term prognosis of induction chemotherapy followed by surgery for N2 non-small cell lung cancer: A retrospective case series study.The Role of Neoadjuvant Trials in Drug Development for Solid Tumors.The role of Cancer-Testis antigens as predictive and prognostic markers in non-small cell lung cancer.How close are we to customizing chemotherapy in early non-small cell lung cancer?Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007.Multicenter Phase II Study Evaluating Two Cycles of Docetaxel, Cisplatin and Cetuximab as Induction Regimen Prior to Surgery in Chemotherapy-Naive Patients with NSCLC Stage IB-IIIA (INN06-Study)Pathologic Stage of Nonsmall Cell Lung Cancer Patients Presenting as Resectable Cases After Neoadjuvant Therapy Did Not Predict the PrognosisEvolution of induction chemotherapy for non-small cell lung cancer over the last 30 years: A surgical appraisalHistopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapyPathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint.Computed tomography RECIST assessment of histopathologic response and prediction of survival in patients with resectable non-small-cell lung cancer after neoadjuvant chemotherapy.A retrospective study: platinum-based induction chemotherapy combined with gemcitabine or paclitaxel for stage IIB-IIIA central non-small-cell lung cancer.Clinical outcomes with perioperative chemotherapy in sarcomatoid carcinomas of the lung.Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancerNeoadjuvant paradigm for accelerated drug development: an ideal model in bladder cancer.Efficacy of S-1 in non-small cell lung cancer.Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.Comparison of mediastinal lymph node status and relapse pattern in clinical stage IIIA non-small cell lung cancer patients treated with neoadjuvant chemotherapy versus upfront surgery: A single center experience.Chemotherapy remains an essential element of personalized care for persons with lung cancers.Neoadjuvant therapy and risk of bronchopleural fistula after lung cancer surgery: a systematic meta-analysis of 14 912 patients.The correlates of benefit from neoadjuvant chemotherapy before surgery in non-small-cell lung cancer: a metaregression analysis.Long-term results of a randomized controlled trial evaluating preoperative chemotherapy in resectable non-small cell lung cancer.The long-term outcomes of induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery.Outcomes and prognostic factors of non-small-cell lung cancer with lymph node involvement treated with induction treatment and surgical resection.Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.Aldehyde dehydrogenase 1 expression in cancer cells could have prognostic value for patients with non-small cell lung cancer who are treated with neoadjuvant therapy: identification of prognostic microenvironmental factors after chemoradiation.Neoadjuvant chemotherapy followed by surgery versus upfront surgery in non-metastatic non-small cell lung cancer: systematic review and meta-analysis of randomized controlled trials.Suppression of TGF-β1 enhances chemosensitivity of cisplatin-resistant lung cancer cells through the inhibition of drug-resistant proteins.Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer.Major pathologic response and RAD51 predict survival in lung cancer patients receiving neoadjuvant chemotherapy.
P2860
Q27010262-82BD74D2-3D8D-455C-91C3-C80872D55503Q30730531-AEE94091-54E3-4E78-B7DF-E09A64CF5992Q33613087-9F96805F-5A68-47CF-9894-6F09391B9745Q33886353-FA90FDD5-D038-447B-B567-73E0D2A2398CQ34917875-7E06F9F6-390A-47B8-AA1E-9DD7AF924897Q35146944-12C78113-EEE4-4B86-90A8-5E6F0815193EQ35147409-EAA2BF9F-8B67-456A-8697-ECB2FE21A23DQ35644940-72E61494-62AF-47E8-9171-969165422DD2Q36195470-1FAAE5E5-78AA-419A-B056-74E24083DE50Q36247875-658038A9-4545-481B-B323-D99AC21AE0DFQ36302496-F7BAEE82-6574-4D7E-85C9-2B1C944135D6Q36525431-28E7C429-097B-47BC-87E5-1AB4CFC6E0C7Q36545344-C1CA9C9A-5972-42C9-A73C-7D23C8180699Q36752521-0F7FBEA4-B492-4E78-B50B-1E3C2E649BBCQ36785118-0BA8A4C2-BA41-404F-9919-8FAB91FF59D6Q36852163-F6C249A5-D784-4EBF-83D2-29F308017533Q37128756-0A002527-687A-4E06-A09E-42E4E3D9124AQ38238511-276A6EBA-BC28-4540-85E6-DC3514D8A54AQ38400481-C4505957-831E-40E1-A682-40AE84E0A93DQ38696794-8CE1C6EA-EE2B-4D96-A142-908F0117FD8BQ38838014-928C770C-DB2C-41BC-9000-2DB7CE79AFEAQ38884871-586F7C9B-5F75-4C88-8698-3B1B1718E9D7Q39572054-50BD84DA-B0EC-4334-B60D-30E2899780B4Q42153374-0EB17B92-25A7-4E43-B244-19B4FE5D6E13Q43055346-B732F519-E03D-44F0-9EBC-249CD2E140C9Q44300864-761944C4-A456-4123-A3D2-9C968C7D745CQ44874525-AC954209-A336-441D-AD44-5F7E5CDF43E0Q45959320-EA102B31-8CFD-464D-88A0-1150D7E7F4F9Q46173157-C4FD2F95-54C8-40DA-A5C9-62A88E2A62DAQ47137416-E16029C5-CD17-4E75-9CA1-0F39371E158AQ47790409-D76BCE81-30FA-46B9-B153-9C792A277567Q52338636-76B4B784-176A-44BF-81EE-5451FEA449D0Q55329630-8204A84C-ACEB-4BC7-B3A7-7DD4E397DD87
P2860
Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@en
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@nl
type
label
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@en
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@nl
prefLabel
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@en
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@nl
P2093
P1476
Survival benefit of neoadjuvan ...... 13 randomized control trials.
@en
P2093
Chao-Yang Liang
Jun-Tang Guo
Nai-Kang Zhou
Wei-An Song
Wei-Min Dai
Xiang-Yang Chu
Xiao-Dong Tian
P304
P356
10.1097/JTO.0B013E3181CD3345
P577
2010-04-01T00:00:00Z